Sotera Health (SHC) Q4 2025: Sterigenics Jumps 10.6% as Margin Expansion Drives 20th Year of Growth

2026-02-24 | By EarningsIQ Research

Sotera Health extended its two-decade growth streak, propelled by strong Sterigenics performance and disciplined financial management. Segment-level execution and margin expansion outpaced headline growth, while capital allocation and customer satisfaction set a foundation for continued momentum. Looking ahead, management’s guidance signals confidence in further pricing power and operational leverage, but investors should monitor early-year volume softness and evolving regulatory dynamics.

Summary

• Sterigenics Outperformance: Core sterilization segment delivered double-digit revenue growth, offsetting commercial softness.
• Margin Expansion Focus: Execution on operating leverage and pricing drove notable margin improvement across business lines.
• Strategic Investments Ahead: Capital deployment targets capacity expansion and end-to-end service leadership for sustained growth.

Performance Analysis

Sotera Health’s 2025 results underscore the business’s resilience and strategic discipline, with consolidated revenue growth of 5.7% and adjusted EBITDA up 8.2%. The company’s flagship Sterigenics, sterilization services for medical and commercial products, posted 10.6% revenue growth in Q4, driven by a combination of 4.3% favorable pricing and 3.7% volume and mix, as well as foreign currency benefit. Segment income improved in line, reflecting both price realization and operational discipline.

Nordion, cobalt-60 isotope supply for sterilization, saw a 12.3% revenue decline due to the timing of harvest schedules, a supply-driven dynamic rather than demand-related weakness. Nelson Labs, laboratory testing and advisory, delivered modest growth with margin expansion, but faced ongoing headwinds in expert advisory services that are expected to ease after Q1 2026. Importantly, company-wide adjusted EBITDA margin hit 51%, up 118 basis points, reflecting both cost control and pricing power. Leverage improved to 3.2x, with $210 million in free cash flow supporting ongoing capital investments and debt reduction.

• Sterigenics Margin Expansion: Pricing and volume mix drove both top-line and segment income gains, reinforcing the moat in core MedTech sterilization.
• Commercial Segment Weakness: Non-MedTech volumes, less than 15% of Sterigenics, remain challenged, with shrinking demand in food and electronics.
• Balance Sheet Strength: Debt paydown and improved liquidity ($940 million available) position the company for strategic flexibility.

Management’s ability to drive pricing, operating leverage, and targeted investment was evident, but early 2026 will test volume momentum and segment mix as regulatory and market headwinds persist in select areas.

Executive Commentary

Strategic Positioning

1. Sterigenics: MedTech Anchor and Pricing Power

Sterigenics continues to anchor Sotera’s growth, with pricing at the high end of the long-term 3% to 4% range and MedTech volumes accelerating. While commercial segment volumes remain volatile and shrinking, the MedTech core—comprising the majority of segment revenue—shows stable to improving demand. Bioprocessing, a small but fast-growing sub-segment, is expected to sustain outsized growth, though from a low base.

2. Diversification and Modalities: X-ray Facility Investment

Strategic capital is being deployed to expand X-ray sterilization capacity, broadening the company’s modality offering beyond ethylene oxide (EO) and gamma. While initial customer utilization is below the typical 40% threshold, management is prioritizing long-term positioning over near-term margin, expecting ramping impact from 2027 onward. This underscores a commitment to full-spectrum solutions and customer stickiness.

3. Nelson Labs: Margin Expansion Amid Advisory Headwinds

Nelson Labs delivered core lab testing growth and expanded margins by over 300 basis points, but continued to face revenue headwinds in expert advisory services. Leadership expects these headwinds to diminish after Q1 2026, with margins stabilizing in the low to mid 30% range for the year. The segment’s transactional nature makes it more variable, but its reputation and service quality remain differentiators in a fragmented market.

4. Capital Allocation and Balance Sheet Discipline

Sotera’s capital strategy remains focused on organic investment, debt reduction, and maintaining flexibility for potential bolt-on acquisitions. The company reduced borrowing costs, paid down $86 million in debt, and enhanced liquidity, while reiterating its commitment to free cash flow targets and measured CapEx aligned with multi-year strategic plans.

5. Customer Satisfaction and Governance

Customer satisfaction exceeded 80%, with Sterigenics scoring even higher, supporting retention and cross-selling. Governance enhancements—including board refreshment and a new lead independent director—signal an ongoing focus on transparency and shareholder alignment.

Key Considerations

Sotera Health’s 2025 performance was driven by core MedTech demand, margin expansion, and prudent capital deployment, but the business faces nuanced challenges in commercial segments, regulatory timelines, and capacity ramp. Investors should weigh the following:

Key Considerations:

• Pricing Sustainability: The ability to sustain high-end pricing gains in Sterigenics will be tested as regulatory and competitive dynamics evolve.
• Early-Year Volume Softness: Both Sterigenics and Nelson Labs typically see softer Q1 performance; weather and shutdowns have amplified this in 2026 guidance.
• Capacity Ramp Risks: The new X-ray facility is opening below the usual customer commitment threshold, creating temporary margin dilution until utilization improves.
• Commercial Segment Volatility: Non-MedTech sterilization remains a drag, with shrinking volumes and customer churn post-pandemic.
• Balance Sheet Flexibility: Improved leverage and liquidity provide optionality for future investment or M&A, but discipline remains key as CapEx rises.

Risks

Volume and mix remain the key swing factors for upside or downside in 2026, especially as MedTech momentum is offset by commercial softness and Nelson Labs advisory headwinds. Regulatory uncertainty, particularly around NESHAP compliance timelines, could shift customer outsourcing decisions. Capacity investments carry ramp risk, with margin dilution possible if utilization lags. Litigation exposure, while not imminent, persists in the background and could resurface as a headline in future periods.

Forward Outlook

For Q1 2026, Sotera Health guided to:

• Sterigenics: Mid-single digit revenue growth, with a soft start due to shutdowns and weather impacts.
• Nelson Labs: Low to mid-single digit revenue decline, with Q1 expected to be the lightest quarter.

For full-year 2026, management raised guidance:

• Revenue: $1.233 billion to $1.251 billion, 5% to 6.5% constant currency growth.
• Adjusted EBITDA: $632 to $641 million, 5.5% to 7% constant currency growth.
• Adjusted EPS: $0.93 to $1.01.
• CapEx: $175 million to $225 million.

Management highlighted several factors that shape the outlook:

• Pricing expected at midpoint of 3% to 4% range, with operational leverage driving margin gains.
• Foreign currency tailwind concentrated in the first half of the year.

Takeaways

Sotera Health’s 2025 results validate its core business model and margin expansion thesis, but the company faces a delicate balance between investing for long-term growth and managing near-term volume volatility.

• Core MedTech Resilience: Sterigenics and Nelson Labs’ MedTech focus underpins stability, while commercial and advisory segments remain volatile.
• Margin and Cash Flow Execution: Operating leverage and disciplined capital allocation support improved profitability and financial flexibility.
• Watch Capacity Ramp and Regulatory Shifts: Utilization of new facilities and NESHAP-driven outsourcing will shape medium-term upside or risk.

Conclusion

Sotera Health delivered on its long-term growth and margin promises, with Sterigenics driving both top-line and profitability gains. Strategic investments in capacity and service breadth position the company for continued leadership, though investors should monitor execution on volume, mix, and regulatory timelines as 2026 unfolds.

Industry Read-Through

Sotera’s results signal robust demand for mission-critical MedTech sterilization, with pricing power and margin expansion likely to benefit other full-spectrum service providers. The X-ray modality investment reflects a broader industry shift toward diversification and resilience in supply chains, as regulatory scrutiny and customer requirements evolve. Fragmentation in lab testing and persistent commercial segment volatility may pressure smaller players, while scale and end-to-end solutions emerge as differentiators. Watch for similar margin and capital discipline themes across healthcare services and life sciences support sectors in upcoming quarters.

SHC Healthcare Medical Services Sterilization MedTech Margin Expansion Capital Allocation Growth Strategy